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and very or extremely large impairments in HRQoL were as-
sociated with itch severity.  Conclusion: Taking the identified 
variables into account may help identify vulnerable groups 
most affected by (severe) itch.  © 2014 S. Karger AG, Basel 
 Introduction 
 Hand eczema (HE) is a frequent and complex disease 
in terms of morphology, location, and especially of etiol-
ogy  [1, 2] . In contrast to acute HE, chronic hand eczema 
(CHE) is characterized by longer disease duration or re-
current episodes and is frequently refractory to topical an-
ti-inflammatory treatment. Patients with CHE complain 
about a variety of symptoms such as itching, burning, 
stinging and pain. Often itching is the dominating symp-
tom, but other dermatoses and diseases may also present 
with itching of the hands, requiring a precise diagnostic 
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 Abstract 
 Background: Itching is a leading symptom of chronic hand 
eczema (CHE) having a great impact on patients. The deter-
minants of itching in CHE are unclear.  Objective: We per-
formed a cross-sectional analysis investigating factors asso-
ciated with the presence and severity of itch in CHE patients 
from the CARPE registry.  Methods: We present baseline data 
on itch in relationship with sociodemographic factors, sever-
ity of CHE, atopy, contact allergy, treatment and patient-
reported outcomes including health-related quality of life 
(HRQoL).  Results: Of 1,051 patients with CHE, 78.1% report-
ed itching. Significant positive associations with itching 
were observed for younger age groups (17–25 and 26–45 
years), for moderate, severe and very severe CHE and for 
small/moderate impairment in HRQoL. Atopic skin diathe-
sis, hardly being able to realize treatment recommendations 
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procedure of this symptom  [3] . However, little is known 
about factors associated with the occurrence and severity 
of itching in CHE. Previous studies have focused on co-
factors of itching in patients with various dermatological 
diseases  [4, 5] or in samples drawn from the general popu-
lation  [6, 7] . An ongoing cross-sectional study in derma-
tological departments of 13 European countries investi-
gates the prevalence and intensity of itch in dermatological 
patients. HE was reported to be among the most frequent 
diseases in patients suffering from (acute) itch  [8] .
 The CARPE registry has been set up to evaluate so-
ciodemographic and clinical characteristics as well as pa-
tient-reported outcomes and treatment modalities in pa-
tients affected by CHE. The aim of this data analysis was to 
identify factors associated with itch and itch severity using 
baseline data from all CHE patients included in CARPE.
 Materials and Methods 
 The CARPE (German acronym: Chronisches Handekzem-
Register zum Patienten-Langzeitmanagement, meaning chronic 
hand eczema registry on long-term patient management) registry 
was established in 2009 as a prospective observational patient co-
hort study. Eligible patients are patients diagnosed with CHE (de-
fined as disease duration  ≥ 3 months or >2 flares within the previ-
ous 12 months), with previous treatment with topical corticoste-
roids, no long-lasting healing under adequate topical treatment 
including corticosteroids and no other dominating active severe 
skin diseases or acute skin infection. Data are collected through 
dermatological examinations and patient questionnaires, e.g. 
through the Physician Global Assessment (PGA) and the Derma-
tology Life Quality Index (DLQI). The design and methodology of 
the CARPE registry have been previously described in detail  [9, 10] 
(for further details see also http://carpe.dermis.net). Ethical ap-
proval was obtained from the University of Heidelberg, Germany 
(No. S-433/2008). The study was established according to the 
guidelines of good clinical practice. Patients gave their written in-
formed consent.
 This analysis is based on data from the physicians’ documenta-
tion as well as patient data assessed at the first examination (base-
line examination). We performed a cross-sectional analysis (n = 
1,051) investigating factors associated with the presence and the 
severity of itch in patients with CHE.
 Primary Outcome 
 Current itching was assessed by the physician by means of a 
verbal rating scale in four categories (none, mild, moderate and 
severe). Itching was evaluated once at baseline examination. ‘Mild’ 
and ‘moderate’ were collapsed into one category. The following 
two variables were used as outcome variables: (1) presence of itch 
(yes vs. no); (2) severity of itch (severe vs. mild/moderate).
 Sociodemographic and Clinical Data 
 The following variables were explored in correlational analyses 
( fig. 1 ): (1) sex (male, female); (2) age (grouped into four catego-
ries: 17–25 years, 26–45 years, 46–64 years,  ≥ 65 years); (3) sever-
ity of CHE (assessed by PGA, supported by the use of a validated 
photographic guide  [11] and rated on a five-point Likert scale: very 
severe, severe, moderate, almost clear, clear); (4) self-assessed se-
verity of CHE, rated on a visual analogue scale ranging from 0 
(clear) to 10 (very severe); (5) diagnosis of CHE (due to a frequent 
clinical overlap seen in CHE, multiple diagnoses were possible); 
(6) atopy (yes vs. no; documented according to the Erlangen Ato-
py Score  [12] ); (7) contact allergy (type IV allergy yes vs. no);
(8) reported treatment of CHE in the 12 months prior to inclusion 
into the registry (topical treatment yes vs. no, UV phototherapy 
yes vs. no, systemic therapy yes vs. no); (9) patient-reported out-
comes: (a) therapy perceived as burdensome, therapy being time-
consuming and experience of unpleasant side effects, rated on a 
four-point Likert scale (not at all, a little, a lot, very much); (b) re-
alization of treatment recommendations, rated on a four-point 
Likert scale (fully, mostly, hardly, not at all); (c) health-related 
quality of life (HRQoL), measured using the DLQI, ranging from 
no impairment to very severe impairment (0–30) and grouped into 
5 categories according to Hongbo et al.  [13] (0–1 = no effect on 
patient’s life, 2–5 = small effect, 6–10 = moderate effect, 11–20
= very large effect, 21–30 = extremely large effect).
 Statistical Analyses 
 A Microsoft Access 2003 database was used for data entry. Sta-
tistical analyses were performed using SPSS (version 20) for Win-
dows. Nominal and ordinal data were analyzed by computing abso-
lute (n) and relative frequencies (%). Continuous variables were an-
alyzed by computing mean and standard deviation (SD). Statistical 
analysis was done in two steps. First χ 2 statistics were used to iden-
Diagnoses
Type of
treatment
Atopy
criteria
Contact
allergy
DLQI
Age
ITCH
Sex
PGA/
severity
of CHE
Patient’s
perspective
on
treatment
satisfaction
 Fig. 1. Variables associated with itch in patients with CHE ex-
plored in correlation analysis. 
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tify variables that were significantly associated with itch and severity 
of itch in univariate analysis. p values <0.05 were considered sig-
nificant. In a second step those variables that were significantly as-
sociated with the presence of itch and itch severity respectively were 
entered into multivariate logistic regression models. Adjusted odds 
ratios with corresponding 95% confidence intervals were computed.
 Results 
 A description of the sample in terms of sociodemo-
graphic and clinical characteristics is provided in  table 1 . 
More than half of the patients were female. The mean age 
was around 48 years (SD 13.8). Around 78% (n = 819) of 
the patients were affected by itch. Of those affected by the 
symptom, 38% (n = 311) reported mild, 28% (n = 233) 
moderate and 34% (n = 275) severe itching.
 Factors Associated with the Presence of Itch 
 Univariate Analysis. As shown in  table 2 , we found sig-
nificant associations between the presence of itch and sex, 
age, PGA, self-assessed severity of CHE, atopic skin di-
athesis, therapy perceived as burdensome, experience of 
unpleasant side effects, realization of treatment recom-
mendations and HRQoL.
Variable % n
Sex (n = 1,051)
Male 46.4 488
Female 53.6 563
Age (n = 1,051)
17 – 25 10.3 108
26 – 45 29.8 313
46 – 64 51.7 543
≥65 8.2 86
PGA (n = 1,049)
Clear 2.0 21
Almost clear 9.5 100
Moderate 23.3 244
Severe 39.7 416
Very severe 25.5 268
Self-assessed severity (n = 1,032)
0 – 1 (clear) 5.4 56
>1 – 3 23.9 247
>3 – 7 45.8 473
>7 – 9 17.3 179
>9 – 10 (very severe) 7.5 77
Itch (n = 1,049)
None 21.9 230
Mild 29.6 311
Moderate 22.2 233
Severe 26.2 275
Diagnoses (n = 1,051)
Irritant contact dermatitis 59.0 620
Atopic HE 36.3 382
Hyperkeratotic fissured eczema 36.5 384
Vesicular HE 29.3 308
Allergic contact dermatitis 17.4 183
Fingertip dermatitis 7.7 81
Other 2.0 21
Atopic skin diathesis (n = 1,045)
No/unlikely/unclear 54.9 577
Yes 44.5 468
Variable % n
Contact allergy (n = 1,028)
No 52.8 543
Yes 47.2 485
Treatment (n = 1,050)
Systemic treatment
No 50.8 533
Yes 49.2 517
UV phototherapy
No 57.0 599
Yes 43.0 451
Patient’s perspective on treatment
Therapy perceived as burdensome (n = 1,011)
Not at all 36.1 365
A little 38.0 384
A lot 16.7 169
Very much 9.2 93
Therapy being time-consuming (n = 1,009)
Not at all 30.9 312
A little 38.9 393
A lot 20.8 210
Very much 9.3 94
Experience of unpleasant side effects (n = 988)
Not at all 52.5 519
A little 26.8 265
A lot 14.3 141
Very much 6.4 63
Realization of treatment recommendations (n = 1,013)
Fully 34.2 346
Mostly 58.5 593
Hardly 6.0 61
Not at all 1.3 13
DLQI (n = 1,027)
No effect (0 – 1) 9.7 100
Small effect (2 – 5) 26.5 272
Moderate effect (6 – 10) 30.6 314
Very large effect (11 – 20) 27.8 285
Extremely large effect (21 – 30) 5.5 56
 Table 1.  Descriptive analysis of factors associated with itch in patients with CHE in the whole sample
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 Multivariate Analysis. Findings from multivariate 
analyses ( table  3 ) revealed significant positive associa-
tions between age groups 17–25 years and 26–45 years, 
very severe, severe or moderately severe CHE as well as a 
moderate or very large impairment of QoL and itch. The 
association between presence of itch and DLQI clearly 
decreased after adjustment. A significant inverse associa-
tion was found between experiencing unpleasant side ef-
fects ‘a little’ and itch.
 Factors Associated with the Severity of Itch 
 Univariate Analysis. We found significant associations 
between the severity of itch and PGA, self-assessed sever-
ity of CHE, atopic skin diathesis, therapy perceived as 
burdensome, therapy perceived as time-consuming, real-
ization of treatment recommendations and DLQI ( ta-
ble 4 ).
 Multivariate Analysis. Multivariate logistic regression 
( table  5 ) revealed that the direction of association re-
mained the same for the variables PGA, atopy, experience 
of unpleasant side effects and DLQI. However, only the 
presence of atopic skin diathesis, hardly any realization of 
treatment recommendation as well as a very and extreme-
ly large impairment of QoL were significantly associated 
with severity of itch.
Variable Itching,
% (n)
p
value
Sex (n = 1,049) 0.031
Male 75.1 (365)
Female 80.6 (454)
Age (n = 1,048) 0.001
17 – 25 91.7 (99)
26 – 45 80.1 (250)
46 – 64 75.3 (408)
≥65 70.9 (61)
PGA (n = 1,048) <0.001
Clear 38.1 (8)
Almost clear 51.0 (51)
Moderate 71.2 (173)
Severe 83.2 (346)
Very severe 89.6 (240)
Self-assessed severity (n = 1,030) <0.001
0 – 1 (clear) 55.4 (31)
>1 – 3 64.4 (159)
>3 – 7 83.0 (391)
>7 – 9 88.8 (159)
>9 – 10 (very severe) 88.3 (68)
Atopic skin diathesis (n = 1,043) 0.004
No/unlikely/unclear 74.7 (430)
Yes 82.0 (383)
Contact allergy (n = 1,026) 0.466
No 77.1 (417)
Yes 79.0 (383)
Diagnoses (n = 1,049)
Irritant contact dermatitis 78.1 (336) 0.966
Atopic HE 85.3 (326) <0.001
Hyperkeratotic fissured eczema 72.8 (279) 0.002
Vesicular HE 83.8 (258) 0.004
Allergic contact dermatitis 86.3 (158) 0.003
Fingertip dermatitis 79.0 (64) 0.832
Other 66.7 (14) 0.196
Variable Itching,
% (n)
p
value
Systemic treatment 
12 months prior to inclusion (n = 1,048) 0.247
No 79.5 (423)
Yes 76.6 (395)
UV phototherapy
12 months prior to inclusion (n = 1,048) 0.097
No 79.9 (477)
Yes 75.6 (341)
Therapy perceived as burdensome (n = 1,009) 0.001
Not at all 73.9 (269)
A little 77.3 (296)
A lot 84.0 (142)
Very much 90.3 (84)
Therapy being time-consuming (n = 1,007) 0.287
Not at all 78.8 (245)
A little 76.0 (298)
A lot 78.1 (164)
Very much 85.1 (80)
Experience of unpleasant side effects (n = 986) 0.038
Not at all 78.7 (407)
A little 74.0 (196)
A lot 83.7 (118)
Very much 87.3 (55)
Realization of treatment recommendations (n = 1,020) <0.001
Fully 68.8 (161)
Mostly 77.8 (360)
Hardly 84.4 (217)
Not at all 90.9 (60)
DLQI (n = 1,025) <0.001
No effect (0 – 1) 54.5 (54)
Small effect (2 – 5) 70.2 (191)
Moderate effect (6 – 10) 81.2 (254)
Very large effect (11 – 20) 86.7 (247)
Extremely large effect (21 – 30) 92.9 (52)
 Table 2.  Presence of itch according to investigated variables (univariate analysis)
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 Discussion 
 To our knowledge this is the first study investigating 
the prevalence and severity of itch in patients affected by 
CHE. The CARPE registry provides data on sociodemo-
graphic, clinical and treatment-related characteristics of 
patients with CHE, which allows the investigation of co-
factors of itch in CHE patients.
 Presence of Itch 
 Our study showed that younger patients were more like-
ly to report itching than older participants, with patients 
aged 17–25 years being most affected by itch, followed by 
the age group 26–45 years. This is in contrast to most find-
ings from previous studies on itch, where older people (es-
pecially those between 50 and 60 years) tended to be more 
affected by itch  [4, 6, 7, 14] . One population-based study 
on chronic itch from Germany found a significant positive 
association between itch and the age group 31–40 years  [7] . 
Results from our multivariate analysis did not show a sig-
nificant difference between the presence of itch and sex, 
meaning that women and men with CHE are equally af-
fected by itch. This is in contrast to results from most of the 
studies on itch considering sex  [4, 5, 15–17] . A cross-sec-
tional study with adults on self-reported skin morbidity in 
Oslo, Norway showed that women reported itching more 
often than men throughout all age groups  [15] .
 Dermatologist-assessed severity of CHE was signifi-
cantly associated with the presence of itch in a linear man-
ner. Since no studies focusing on the presence and sever-
ity of itch in patients with HE have yet been conducted, 
further evidence is needed to confirm our results.
 Our results show that the experience of unpleasant 
side effects indicated by the patients as ‘a little’ was asso-
ciated with less itch. Patients reporting little experience of 
unpleasant side effects may be on effective treatment not 
imposing a heavy burden on them. If this is the case, itch 
may also be well controlled or not present. However, this 
remains speculative and the finding needs to be verified 
in future studies.
 Moderate and extremely large effects on QoL, mea-
sured by the DLQI, were significantly associated with the 
presence of itch in patients with CHE. A study analyzing 
different dermatological diseases found a significant cor-
relation between the presence of itch and a lower QoL 
measured by DLQI  [18] . A Turkish study investigated a 
significant relationship between itch and DLQI scores 
 ≥ 10 in psoriasis patients  [19] . Patients affected by pem-
phigus vulgaris showed significantly increased DLQI 
scores when itching was reported  [20] . Similar results 
 Table 3.  Results from multivariate logistic regression (outcome: 
presence of itch)
Variable Adjusted OR 
(95% CI)
Sex (n = 1,049)
Male 1.0
Female 1.29 (0.91 – 1.84)
Age (n = 1,048)
17 – 25 4.68 (1.76 – 12.46)
26 – 45 2.02 (1.05 – 3.87)
46 – 64 1.65 (0.90 – 3.03)
≥65 1.0
PGA (n = 1,048)
Clear 1.0
Almost clear 2.43 (0.81 – 7.31)
Moderate 4.43 (1.51 – 13.02)
Severe 6.14 (2.07 – 18.16)
Very severe 9.34 (2.91 – 29.97)
Self-assessed severity (n = 1,030)
0 – 1 (clear) 1.0
>1 – 3 1.00 (0.50 – 2.00)
>3 – 7 1.70 (0.81 – 3.58)
>7 – 9 2.46 (0.97 – 6.24)
>9 – 10 (very severe) 2.08 (0.63 – 6.87)
Atopic skin diathesis (n = 1,043)
No/unlikely/unclear 1.0
Yes 1.29 (0.90 – 1.86)
Therapy perceived as burdensome (n = 1,009)
Not at all 1.0
A little 1.16 (0.76 – 1.78)
A lot 1.47 (0.77 – 2.80)
Very much 2.48 (0.92 – 6.67)
Experience of unpleasant side effects (n = 986)
Not at all 1.0
A little 0.51 (0.33 – 0.79)
A lot 0.58 (0.30 – 1.14)
Very much 0.51 (0.18 – 1.44)
Realization of treatment recommendations (n = 1,020)
Fully 1.0
Mostly 1.18 (0.82 – 1.71)
Hardly 2.68 (0.76 – 9.41)
Not at all 0.44 (0.12 – 1.63)
DLQI (n = 1,025)
No effect (0 – 1) 1.0
Small effect (2 – 5) 1.39 (0.80 – 2.41)
Moderate effect (6 – 10) 1.87 (1.03 – 3.41)
Very large effect (11 – 20) 2.05 (1.02 – 4.10)
Extremely large effect (21 – 30) 2.84 (0.83 – 9.79)
CI = Confidence interval; OR = odds ratio. Bold indicates
p < 0.05.
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were found in psoriatic patients with itch, who had sig-
nificantly decreased HRQoL compared to patients not 
affected by itch  [21] . A cross-sectional study with pa-
tients affected by systemic sclerosis from Canada mea-
sured QoL according to the 36-Item Short Form Health 
Survey. Patients suffering from pruritus had a signifi-
cantly greater negative impact on QoL than patients 
without pruritus  [22] . A cross-sectional study in 13 Eu-
ropean countries with 250 consecutive patients and 125 
healthy controls demonstrated that patients reporting 
itch were more depressed than those without itch, had 
more anxiety and a larger impact on QoL measured by 
the DLQI  [23] .
 Severity of Itch 
 Our study demonstrates that patients with atopy seem 
to be more likely to suffer from a severe form of itching 
than patients with no or an uncertain atopy. It is well 
known that atopic hand dermatitis is very frequently ac-
companied by itch, but so far there are no studies that 
specifically address this issue. A web-based questionnaire 
study on itch characteristics showed that atopic derma-
titis responders experienced itch more frequently and 
more intensely when compared to subjects suffering from 
psoriasis  [24] . In patients with occupational CHE, those 
with irritant contact dermatitis reported significantly less 
intense itching than patients with irritant-induced atopic 
HE  [16] . Patients with severe CHE reported more intense 
itching than patients with non-severe CHE, and individu-
als with atopic dermatitis had higher visual analogue scale 
scores for itch than patients with exclusive HE  [16] . This 
confirms our results showing a significant association be-
tween atopic diathesis and severe itch.
Variable Severe itching,
% (n)
p
value
Sex (n = 819) 0.155
Male 31.0 (113)
Female 35.7 (162)
Age (n = 818) 0.781
17 – 25 36.4 (36)
26 – 45 33.6 (84)
46 – 64 32.4 (132)
≥65 37.7 (23)
PGA (n = 818) <0.001
Clear 25.0 (2)
Almost clear 17.6 (9)
Moderate 19.7 (34)
Severe 30.1 (104)
Very severe 52.5 (126)
Self-assessed severity (n = 808) <0.001
0 – 1 (clear) 16.1 (5)
>1 – 3 18.2 (29)
>3 – 7 32.2 (126)
>7 – 9 42.1 (67)
>9 – 10 (very severe) 63.2 (43)
Atopic skin diathesis (n = 813) 0.004
No/unlikely/unclear 28.8 (124)
Yes 38.4 (147)
Contact allergy (n = 800) 0.580
No 32.6 (136)
Yes 34.5 (132)
Systemic treatment
12 months prior to inclusion (n = 818) 0.131
No 31.2 (132)
Yes 36.2 (143)
Variable Severe itching,
% (n)
p
value
UV phototherapy
12 months prior to inclusion (n = 818) 0.385
No 32.3 (154)
Yes 35.2 (120)
Therapy perceived as burdensome (n = 791) <0.001
Not at all 34.9 (94)
A little 26.7 (79)
A lot 28.9 (41)
Very much 53.6 (45)
Therapy being time-consuming (n = 787) 0.010
Not at all 35.5 (87)
A little 25.8 (77)
A lot 39.6 (65)
Very much 36.2 (29)
Experience of unpleasant side effects (n = 776) 0.037
Not at all 29.7 (121)
A little 33.7 (66)
A lot 32.2 (38)
Very much 49.1 (27)
Realization of treatment recommendations (n = 792) <0.001
Fully 27.2 (70)
Mostly 32.8 (154)
Hardly 52.6 (30)
Not at all 66.7 (6)
DLQI (n = 798) <0.001
No effect (0 – 1) 14.8 (8)
Small effect (2 – 5) 20.9 (40)
Moderate effect (6 – 10) 27.2 (69)
Very large effect (11 – 20) 45.3 (112)
Extremely large effect (21 – 30) 65.4 (34)
 Table 4.  Severity of itch according to the investigated variables (univariate analysis)
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 Difficulties in the realization of treatment recommen-
dations were associated with severe itching, suggesting 
that the previous treatment of CHE had not sufficiently 
addressed itching. Another explanation may be that se-
vere CHE is associated with more intense itch  [16] , which 
can complicate its treatment. One may also speculate that 
physicians tend to underestimate itch in CHE, leading to 
a reduced awareness and recording of this symptom, also 
in clinical studies.
 Severity of itch in patients with CHE was significantly 
associated with impaired QoL (assessed by the DLQI) in 
a linear manner. Similar results were shown in patient 
populations affected by other skin diseases accompanied 
by itch, such as urticaria  [25] and psoriasis  [21, 26, 27] . 
One study investigating psychological factors associated 
with hand dermatoses showed that high stress responders 
stated significantly higher values for itch  [28] .
 Limitations 
 In the CARPE registry, itch is only measured as one 
variable. As solely the presence of itch was asked, the re-
sults presented here refer to current itch. Details like 
course, localization and accompanying sensations like 
pain, burning or stinging would have been of interest as 
well. An assessment of itch according to the visual ana-
logue scale is recommended for studies on itch  [29, 30] , 
but we relied on itch measured by a verbal rating scale. All 
findings presented in this paper are only representative 
for patients with CHE refractory to topical treatment. Be-
cause of the cross-sectional design of our study, caution 
needs to be exercised concerning suggestions about a 
causal relationship between the presence or severity of 
itch and the investigated variables. Further prospective 
and longitudinal studies may permit to establish a causal 
relationship. Our current analyses should be considered 
exploratory in nature. Nevertheless, these are the first 
findings on a variety of factors associated with the pres-
ence and severity of itch in patients with CHE.
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 Table 5.  Results from multivariate logistic regression (outcome: 
severe itching)
Variable Adjusted OR
(95% CI)
PGA (n = 818)
Clear 1.0
Almost clear 0.99 (0.10 – 10.27)
Moderate 0.89 (0.09 – 8.74)
Severe 1.26 (0.13 – 12.24)
Very severe 2.16 (0.22 – 21.06)
Self-assessed severity (n = 808)
0 – 1 (clear) 1.0
>1 – 3 0.96 (0.28 – 3.29)
>3 – 7 1.40 (0.41 – 4.79)
>7 – 9 1.37 (0.38 – 4.50)
>9 – 10 (very severe) 2.49 (0.62 – 10.01)
Atopic skin diathesis (n = 813)
No/unlikely/unclear 1.0
Yes 1.43 (1.01 – 2.03)
Therapy perceived as burdensome (n = 791)
Not at all 1.0
A little 0.73 (0.45 – 1.17)
A lot 0.54 (0.28 – 1.04)
Very much 1.15 (0.52 – 2.57)
Therapy being time-consuming (n = 787)
Not at all 1.0
A little 0.65 (0.41 – 1.04)
A lot 0.76 (0.42 – 1.40)
Very much 0.33 (0.15 – 0.73)
Experience of unpleasant side effects (n = 776)
Not at all 1.0
A little 1.31 (0.82 – 2.11)
A lot 0.83 (0.44 – 1.56)
Very much 1.36 (0.56 – 3.29)
Realization of treatment recommendations (n = 792)
Fully 1.0
Mostly 1.20 (0.82 – 1.77)
Hardly 2.03 (1.01 – 4.06)
Not at all 1.98 (0.40 – 9.79)
DLQI (n = 798)
No effect (0 – 1) 1.0
Small effect (2 – 5) 1.26 (0.52 – 3.02)
Moderate effect (6 – 10) 1.53 (0.64 – 3.65)
Very large effect (11 – 20) 3.00 (1.21 – 7.37)
Extremely large effect (21 – 30) 7.06 (2.30 – 21.64)
CI = Confidence interval; OR = odds ratio. Bold indicates
p < 0.05.
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